Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

Tecan Group Ltd.. (12/1/14). "Press Release: Tecan Issues H2 2014 Trading Update". Männedorf.

Organisations Organisation Tecan Group Ltd. (SIX Swiss Exchange: TECN)
  Group Tecan (Group)
  Organisation 2 IBL International GmbH
  Group Tecan (Group)
Products Product laboratory automation equipment
  Product 2 immunoassay (diagnostics, antibody-antigen-test)
Index term Index term IBL International–Tecan: investment, 201407 acquisition €29m in cash
Persons Person Martyr, David (Tecan 201202–201903 announced CEO for 10/12 before Leica Microsystems RETIRED 4/19)
  Person 2 Eugster, Rudolf (Tecan 200212– CFO)

> Good sales growth trend in the second half of 2014: mid single-digit organic growth in local currencies expected

> Strong recovery in the Partnering Business with anticipated double-digit sales growth in local currencies

> IBL International integration going well; expected to exceed sales outlook

> Organic sales outlook for financial year 2014 adjusted to low single-digit percentage growth in local currencies

> Confirming target for total Group operating profitability

> Reconfirming strongly accelerated growth in 2015

The Tecan Group (SIX Swiss Exchange: TECN) today issued a trading update for the second half of 2014.

Tecan CEO David Martyr commented: "After a difficult first half with declining sales and our Partnering Business suffering from delays in order placement from two large customer accounts, it is good to see the growth trend in the second half is supported by the Partnering Business recouping the shortfall from the beginning of the year. We are now on a trajectory we had anticipated for the full year and with the planned ramping up of major Partnering Business projects we expect strongly accelerated growth in 2015."

Tecan sees a good trend in sales and expects to generate organic sales growth in the mid single-digit percentage range in the second half of 2014. After recording declining sales in the first half of the year, the Partnering Business recovered strongly and is anticipated to post double-digit sales growth in the second half. The Life Sciences Business, as already reported for the first half-year, has been progressing well in the established markets in North America and Europe compared to 2013. However, as reported before, the business environment in China remains challenging. Although sales in the region have been improving in the second half compared to the beginning of the year, a return to normal trends in China is only expected in the course of 2015.

The integration of IBL International, included in the consolidated financial statements of the Tecan Group since August 1, 2014, is progressing well and sales for the five months period are expected to exceed the initial outlook of a mid single-digit million Swiss franc sales contribution.

Momentum of order flow has been particularly strong for the Partnering Business in recent weeks. However, not all orders can be converted to sales in fiscal year 2014 due to the late timing of some of those orders. Therefore, the organic sales outlook for the financial year 2014 is adjusted to low single-digit percentage growth in local currencies compared to in the mid single-digit percentage range previously communicated.

Tecan is confirming the outlook for the total Group operating profitability, including IBL International, which was given at the half-year reporting on August 13, 2014.

Tecan is also reconfirming the expectation of strongly accelerated sales growth during 2015. Total Group sales are anticipated to increase with a double-digit rate in local currencies. This strong growth will be driven by a continued ramp up of major Partnering Business platforms and further supported by additional product introductions in both divisions.

About Tecan

Tecan ( is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2013, Tecan generated sales of CHF 388 million (USD 419 million; EUR 316 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group

Dr. Rudolf Eugster Martin Brändle
Chief Financial Officer Head of Corporate Communications & Investor Relations Tel. +41 (0) 44 922 84 30 Fax +41 (0) 44 922 88 89

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Tecan (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top